Crinetics Pharmaceuticals (CRNX) Share-based Compensation (2017 - 2026)

Crinetics Pharmaceuticals' Share-based Compensation history runs 10 years deep, the most recent figure standing at $29.7 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 44.94% year-over-year to $29.7 million; the TTM figure through Mar 2026 stood at $100.2 million (up 31.17% YoY), while the FY2025 annual figure was $91.0 million, up 31.18% from the prior year.
• Share-based Compensation for Q1 2026 stood at $29.7 million, up from $21.7 million in the prior quarter.
• The five-year high for Share-based Compensation was $29.7 million in Q1 2026, with the low at $5.8 million in Q1 2022.
• The 5-year median for Share-based Compensation is $13.5 million (2024), against an average of $15.3 million.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation soared 86.14% in 2024, then advanced 15.26% in 2025.
• Crinetics Pharmaceuticals' Share-based Compensation stood at $7.9 million in 2022, then jumped by 46.16% to $11.6 million in 2023, then soared by 62.22% to $18.8 million in 2024, then gained by 15.26% to $21.7 million in 2025, then surged by 36.65% to $29.7 million in 2026.
• Business Quant data shows CRNX's Share-based Compensation at $29.7 million in Q1 2026, $21.7 million in Q4 2025, and $22.7 million in Q3 2025.